ECSP21093541A - Compuestos para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents
Compuestos para el tratamiento de enfermedades y trastornos asociados con brafInfo
- Publication number
- ECSP21093541A ECSP21093541A ECSENADI202193541A ECDI202193541A ECSP21093541A EC SP21093541 A ECSP21093541 A EC SP21093541A EC SENADI202193541 A ECSENADI202193541 A EC SENADI202193541A EC DI202193541 A ECDI202193541 A EC DI202193541A EC SP21093541 A ECSP21093541 A EC SP21093541A
- Authority
- EC
- Ecuador
- Prior art keywords
- braf
- disorders
- compounds
- treatment
- associated diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se adjunta resumen de la invención
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868581P | 2019-06-28 | 2019-06-28 | |
| US202063021410P | 2020-05-07 | 2020-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21093541A true ECSP21093541A (es) | 2022-01-31 |
Family
ID=71465389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202193541A ECSP21093541A (es) | 2019-06-28 | 2021-12-28 | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11414404B2 (es) |
| EP (1) | EP3990437A1 (es) |
| JP (1) | JP7169469B2 (es) |
| KR (1) | KR102712548B1 (es) |
| CN (1) | CN114026073B (es) |
| AU (1) | AU2020302352B2 (es) |
| BR (1) | BR112021025102A2 (es) |
| CA (1) | CA3144859C (es) |
| CO (1) | CO2021017438A2 (es) |
| CR (1) | CR20210626A (es) |
| CU (1) | CU20210098A7 (es) |
| EC (1) | ECSP21093541A (es) |
| IL (1) | IL288214B2 (es) |
| MA (1) | MA56387A (es) |
| MX (1) | MX2021015903A (es) |
| PE (1) | PE20220341A1 (es) |
| PH (1) | PH12021552913A1 (es) |
| TW (1) | TWI817018B (es) |
| UY (1) | UY38767A (es) |
| WO (1) | WO2020261156A1 (es) |
| ZA (1) | ZA202201329B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PE20221027A1 (es) * | 2019-12-10 | 2022-06-16 | Hoffmann La Roche | Nuevos inhibidores de braf como rompedores de la paradoja |
| SI4073065T1 (sl) * | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| CN113521269A (zh) * | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
| US12303509B2 (en) * | 2020-06-09 | 2025-05-20 | Pfizer Inc. | Compounds for the treatment of BRAF-associated diseases and disorders |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| CN117940133A (zh) * | 2021-06-08 | 2024-04-26 | C4医药公司 | 用于突变braf的降解的治疗剂 |
| EP4351577A1 (en) * | 2021-06-09 | 2024-04-17 | F. Hoffmann-La Roche AG | Combination therapy for cancer treatment |
| CN118201615A (zh) * | 2021-11-04 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物用于治疗癌症的新用途 |
| JP2024545073A (ja) * | 2021-12-08 | 2024-12-05 | アレイ バイオファーマ インコーポレイテッド | Ｎ－（２－クロロ－３－（（５－クロロ－３－メチル－４－オキソ－３，４－ジヒドロキナゾリン－６－イル）アミノ）－４－フルオロフェニル）－３－フルオロアゼチジン－１－スルホンアミドの結晶形態 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN120265291A (zh) * | 2022-11-18 | 2025-07-04 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物的新用途和制剂 |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| WO2025029683A1 (en) | 2023-07-28 | 2025-02-06 | Cogent Biosciences, Inc. | Pi3k inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE449605T1 (de) | 2002-03-13 | 2009-12-15 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek- hemmer |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| JP4768628B2 (ja) | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの二環系阻害剤及びその使用方法 |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| US20090118261A1 (en) | 2004-08-31 | 2009-05-07 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| WO2007044084A2 (en) | 2005-05-18 | 2007-04-19 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
| US20090163525A1 (en) | 2006-04-05 | 2009-06-25 | Astrazeneca Ab | Substituted quinazolines with anti-cancer activity |
| EP2007737A2 (en) | 2006-04-05 | 2008-12-31 | AstraZeneca AB | Chemical compounds |
| WO2007119055A1 (en) | 2006-04-18 | 2007-10-25 | Astrazeneca Ab | Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| EP3094627B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CA3008312A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
| EP3878850A1 (en) | 2016-12-22 | 2021-09-15 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| AU2018338098B2 (en) * | 2017-09-20 | 2024-02-22 | Abm Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| WO2019071351A1 (en) | 2017-10-12 | 2019-04-18 | Trillium Therapeutics Inc. | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| CN113711012A (zh) | 2018-09-14 | 2021-11-26 | 联合利华知识产权控股有限公司 | 免洗型化妆品组合物保护皮肤免受污染的功效的评估 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
-
2020
- 2020-06-23 TW TW109121279A patent/TWI817018B/zh active
- 2020-06-24 MA MA056387A patent/MA56387A/fr unknown
- 2020-06-24 MX MX2021015903A patent/MX2021015903A/es unknown
- 2020-06-24 BR BR112021025102A patent/BR112021025102A2/pt unknown
- 2020-06-24 US US16/910,688 patent/US11414404B2/en active Active
- 2020-06-24 PE PE2021002078A patent/PE20220341A1/es unknown
- 2020-06-24 PH PH1/2021/552913A patent/PH12021552913A1/en unknown
- 2020-06-24 CA CA3144859A patent/CA3144859C/en active Active
- 2020-06-24 JP JP2021576777A patent/JP7169469B2/ja active Active
- 2020-06-24 AU AU2020302352A patent/AU2020302352B2/en active Active
- 2020-06-24 IL IL288214A patent/IL288214B2/en unknown
- 2020-06-24 CU CU2021000098A patent/CU20210098A7/es unknown
- 2020-06-24 EP EP20736786.3A patent/EP3990437A1/en active Pending
- 2020-06-24 CN CN202080047143.1A patent/CN114026073B/zh active Active
- 2020-06-24 CR CR20210626A patent/CR20210626A/es unknown
- 2020-06-24 WO PCT/IB2020/055992 patent/WO2020261156A1/en active Application Filing
- 2020-06-24 KR KR1020217042157A patent/KR102712548B1/ko active Active
- 2020-06-26 UY UY0001038767A patent/UY38767A/es not_active Application Discontinuation
-
2021
- 2021-12-20 CO CONC2021/0017438A patent/CO2021017438A2/es unknown
- 2021-12-28 EC ECSENADI202193541A patent/ECSP21093541A/es unknown
-
2022
- 2022-01-27 ZA ZA2022/01329A patent/ZA202201329B/en unknown
- 2022-05-16 US US17/745,346 patent/US11634409B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11634409B2 (en) | 2023-04-25 |
| IL288214A (en) | 2022-01-01 |
| US20220289721A1 (en) | 2022-09-15 |
| CA3144859A1 (en) | 2020-12-30 |
| EP3990437A1 (en) | 2022-05-04 |
| JP7169469B2 (ja) | 2022-11-10 |
| UY38767A (es) | 2021-01-29 |
| TWI817018B (zh) | 2023-10-01 |
| PE20220341A1 (es) | 2022-03-14 |
| CN114026073A (zh) | 2022-02-08 |
| IL288214B2 (en) | 2025-03-01 |
| US20200407344A1 (en) | 2020-12-31 |
| TW202114996A (zh) | 2021-04-16 |
| US11414404B2 (en) | 2022-08-16 |
| MX2021015903A (es) | 2022-02-03 |
| CU20210098A7 (es) | 2022-06-06 |
| WO2020261156A1 (en) | 2020-12-30 |
| AU2020302352A1 (en) | 2022-01-20 |
| JP2022539056A (ja) | 2022-09-07 |
| AU2020302352B2 (en) | 2023-03-23 |
| IL288214B1 (en) | 2024-11-01 |
| KR20220011712A (ko) | 2022-01-28 |
| CN114026073B (zh) | 2024-08-23 |
| CO2021017438A2 (es) | 2022-01-17 |
| CR20210626A (es) | 2022-02-08 |
| BR112021025102A2 (pt) | 2022-01-25 |
| PH12021552913A1 (en) | 2022-04-04 |
| KR102712548B1 (ko) | 2024-09-30 |
| ZA202201329B (en) | 2023-09-27 |
| CA3144859C (en) | 2023-09-12 |
| MA56387A (fr) | 2022-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| EA201790992A1 (ru) | Иммунорегуляторные агенты | |
| EP3890725A4 (en) | Compositions for treating dermatological diseases | |
| EA201892740A2 (ru) | Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk) | |
| JOP20220054A1 (ar) | علاج اعتلال الدماغ syngap1 | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| IL280664A (en) | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | |
| EP3583113A4 (en) | USE OF TGF-ALPHA FOR THE TREATMENT OF ILLNESSES AND CONDITIONS | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| EP3844156A4 (en) | TREATMENT OF HEPATIC DISORDERS | |
| EP3818085A4 (en) | COMPOSITIONS AND THEIR USES FOR TREATING A DISEASE OR CONDITION | |
| CL2021002182A1 (es) | Formulación de anticuerpos terapéuticos | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EP3927428C0 (en) | NORKETOTIFEN FOR THE TREATMENT OF RESPIRATORY DISORDERS | |
| EP3773686A4 (en) | ALKALINE PHOSPHATASE AGENTS FOR THE TREATMENT OF DISORDERS DUE TO EXPOSURE TO RADIATION | |
| EP4392423A4 (en) | QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DISEASE | |
| CL2022000294A1 (es) | Composiciones biofarmacéuticas y procedimientos conexos. | |
| MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| PL3860998T3 (pl) | Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj |